DAX ®13.054,80-0,65%TecDAX ®3.037,12-0,16%Dow Jones27.677,79+0,10%NASDAQ 1008.308,40+0,14%
finanztreff.de

PRESS RELEASE: Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019

| Quelle: Dow Jones Newsw... | Lesedauer etwa 5 min. | Text vorlesen Stop Pause Fortsetzen


DGAP-News: MorphoSys AG / Key word(s): Miscellaneous
Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019

2019-10-21 / 22:01
The issuer is solely responsible for the content of this announcement.

Planegg/Munich, Germany, October 21, 2019

*Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019*

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; Nasdaq: MOR)
will publish its first nine months' 2019 results on October 29, 2019 at
10:00 pm CET ( 9:00 pm GMT; 5:00 pm EDT).

The Management team of MorphoSys AG will host a conference call and webcast
on October 30, 2019 at 2:00 pm CET ( 1:00 pm GMT; 9:00 am EDT) to present
MorphoSys's third quarter results 2019 and provide further details on the
Company's latest developments.

*Date of the conference *Wednesday, October 30, 2019*
call:*
*Time:* 2:00 * pm CET ( 1:00 pm GMT, 9:00 am
EDT)*
*Dial-in numbers:*
*Germany:* *+49 69 201 744 220*
*United Kingdom:* *+44 203 009 2470*
*USA: * *+1 877 423 0830*
*Participant PIN:* *97683318#*

Participants are kindly requested to dial in up to 10 minutes before the
call to ensure a secure line and a prompt start.

The presentation slides and webcast link will be available at the Company's
website at http://www.morphosys.com/conference-calls [1]

A replay of the conference will also be available at the corporate website
following the live event.

About MorphoSys:
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company
dedicated to the discovery, development and commercialization of
exceptional, innovative therapies for patients suffering from serious
diseases. The focus is on cancer. Based on its leading expertise in
antibody, protein and peptide technologies, MorphoSys, together with its
partners, has developed and contributed to the development of more than 100
product candidates, of which 29 are currently in clinical development. In
2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis,
became the first drug based on MorphoSys's antibody technology to receive
regulatory approval. The Company's most advanced proprietary product
candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough
therapy designation for the treatment of patients with relapsed/refractory
diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany,
the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US
Inc., has approximately 370 employees. More information at
https://www.morphosys.com [2].

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio
Pharma(R), LanthioPep(R) and ENFORCERTM are trademarks of the MorphoSys
Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.

_MorphoSys forward looking statements_
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies. The forward-looking statements contained
herein represent the judgment of MorphoSys as of the date of this release
and involve known and unknown risks and uncertainties, which might cause the
actual results, financial condition and liquidity, performance or
achievements of MorphoSys, or industry results, to be materially different
from any historic or future results, financial conditions and liquidity,
performance or achievements expressed or implied by such forward-looking
statements. In addition, even if MorphoSys's results, performance, financial
condition and liquidity, and the development of the industry in which it
operates are consistent with such forward-looking statements, they may not
be predictive of results or developments in future periods. Among the
factors that may result in differences are that MorphoSys's expectations may
be incorrect, the inherent uncertainties associated with competitive
developments, clinical trial and product development activities and
regulatory approval requirements (including that MorphoSys may fail to
obtain regulatory approval for tafasitamab (MOR208) and that data from
MorphoSys's ongoing clinical research programs may not support registration
or further development of its product candidates due to safety, efficacy or
other reasons), MorphoSys's reliance on collaborations with third parties,
estimating the commercial potential of its development programs and other
risks indicated in the risk factors included in MorphoSys's Annual Report on
Form 20-F and other filings with the U.S. Securities and Exchange
Commission. Given these uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
MorphoSys expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based or that may affect the
likelihood that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.

*For more information, please contact:*

*MorphoSys A**G*

Dr. Sarah Fakih
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26663
Sarah.Fakih@morphosys.com
Dr. Julia Neugebauer
Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-179
Julia.Neugebauer@morphosys.com
Dr. Verena Kupas
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26814
Verena.Kupas@morphosys.com

2019-10-21 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: investors@morphosys.com
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 893605

End of News DGAP News Service

893605 2019-10-21


1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=93d251a80a82730f0976114641593866&application_id=893605&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=3e1886fbba4d35045db9993a27da4719&application_id=893605&site_id=vwd&application_name=news


(END) Dow Jones Newswires

October 21, 2019 16:01 ET ( 20:01 GMT)
Werbung

Passende Hebelprodukte von

WKN Bezeichnung Hebel
Long  DS4T7R MORPHOSY WaveUnlimited S 123.684 (DBK) 13,659
Werbung

Das könnte Sie auch interessieren

News-Suche

Suchbegriff:

Aktuelle Videos

zur Mediathek
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Was wünschen Sie sich von der Großen Koalition?
Jetzt abstimmen!
Alle Umfragen ansehen